2422 related articles for article (PubMed ID: 32271354)
21. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Shitara K; Van Cutsem E; Bang YJ; Fuchs C; Wyrwicz L; Lee KW; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Mansoor W; Braghiroli MI; Karaseva N; Caglevic C; Villanueva L; Goekkurt E; Satake H; Enzinger P; Alsina M; Benson A; Chao J; Ko AH; Wainberg ZA; Kher U; Shah S; Kang SP; Tabernero J
JAMA Oncol; 2020 Oct; 6(10):1571-1580. PubMed ID: 32880601
[TBL] [Abstract][Full Text] [Related]
22. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
24. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Kato R; Hayashi H; Chiba Y; Miyawaki E; Shimizu J; Ozaki T; Fujimoto D; Toyozawa R; Nakamura A; Kozuki T; Tanaka K; Teraoka S; Usui K; Nishino K; Hataji O; Ota K; Ebi N; Saeki S; Akazawa Y; Okuno M; Yamamoto N; Nakagawa K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066647
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Peng TR; Lin HH; Tsai FP; Wu TW
Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
27. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A
Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059
[TBL] [Abstract][Full Text] [Related]
28. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
29. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
[TBL] [Abstract][Full Text] [Related]
30. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
31. Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.
Liu J; Chen M; Gao X; Liu X; Zhao J; Pan R; Zhong W; Xu Y; Wang M
Thorac Cancer; 2023 Mar; 14(8):773-778. PubMed ID: 36725772
[TBL] [Abstract][Full Text] [Related]
32. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
34. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
[TBL] [Abstract][Full Text] [Related]
35. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
[TBL] [Abstract][Full Text] [Related]
36. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
38. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
39. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
40. Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Ishida M; Morimoto K; Yamada T; Shiotsu S; Chihara Y; Yamada T; Hiranuma O; Morimoto Y; Iwasaku M; Tokuda S; Takeda T; Takayama K
Thorac Cancer; 2022 Jan; 13(2):173-181. PubMed ID: 34791812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
